199 related articles for article (PubMed ID: 29633884)
21. Pathological Circulating Factors in Moyamoya Disease.
Fang YC; Wei LF; Hu CJ; Tu YK
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567654
[TBL] [Abstract][Full Text] [Related]
22. Moyamoya disease: a review of histopathology, biochemistry, and genetics.
Weinberg DG; Arnaout OM; Rahme RJ; Aoun SG; Batjer HH; Bendok BR
Neurosurg Focus; 2011 Jun; 30(6):E20. PubMed ID: 21631222
[TBL] [Abstract][Full Text] [Related]
23. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune reaction in its pathogenesis.
Fujimura M; Fujimura T; Kakizaki A; Sato-Maeda M; Niizuma K; Tomata Y; Aiba S; Tominaga T
Brain Res; 2018 Jan; 1679():39-44. PubMed ID: 29174692
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo.
Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547
[TBL] [Abstract][Full Text] [Related]
25. A nationwide survey on unilateral moyamoya disease in Japan.
Hayashi K; Horie N; Izumo T; Nagata I
Clin Neurol Neurosurg; 2014 Sep; 124():1-5. PubMed ID: 24976021
[TBL] [Abstract][Full Text] [Related]
26. Caspase-3-dependent apoptosis in middle cerebral arteries in patients with moyamoya disease.
Takagi Y; Kikuta K; Sadamasa N; Nozaki K; Hashimoto N
Neurosurgery; 2006 Oct; 59(4):894-900; discussion 900-1. PubMed ID: 17038954
[TBL] [Abstract][Full Text] [Related]
27. Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease.
He S; Zhang J; Liu Z; Wang Y; Hao X; Wang X; Zhou Z; Ye X; Zhao Y; Zhao Y; Wang R
Stroke; 2023 Dec; 54(12):3153-3164. PubMed ID: 37886851
[TBL] [Abstract][Full Text] [Related]
28. Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.
Xue Y; Zhang Q; Wang LJ; Tu WJ; Zhao J
Curr Stem Cell Res Ther; 2023; 18(6):733-739. PubMed ID: 35674309
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity.
Ottino P; Finley J; Rojo E; Ottlecz A; Lambrou GN; Bazan HE; Bazan NG
Mol Vis; 2004 May; 10():341-50. PubMed ID: 15162095
[TBL] [Abstract][Full Text] [Related]
30. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease.
Takagi Y; Kikuta K; Nozaki K; Fujimoto M; Hayashi J; Imamura H; Hashimoto N
Neurosurgery; 2007 Feb; 60(2):338-45; discussion 345. PubMed ID: 17290185
[TBL] [Abstract][Full Text] [Related]
31. Vulnerability to shear stress caused by altered peri-endothelial matrix is a key feature of Moyamoya disease.
Matsuo M; Nadanaka S; Soga M; Sugiyama T; Serigano S; Shimano K; Ichinose F; Nakamura T; Maeda T; Houkin K; Era T; Kitagawa H
Sci Rep; 2021 Jan; 11(1):1552. PubMed ID: 33452387
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients.
Hitomi T; Habu T; Kobayashi H; Okuda H; Harada KH; Osafune K; Taura D; Sone M; Asaka I; Ameku T; Watanabe A; Kasahara T; Sudo T; Shiota F; Hashikata H; Takagi Y; Morito D; Miyamoto S; Nakao K; Koizumi A
Biochem Biophys Res Commun; 2013 Aug; 438(1):13-9. PubMed ID: 23850618
[TBL] [Abstract][Full Text] [Related]
33. TGFβ1 as a Predictive Biomarker for Collateral Formation Within Ischemic Moyamoya Disease.
Chen Y; Tang M; Li H; Liu H; Wang J; Huang J
Front Neurol; 2022; 13():899470. PubMed ID: 35873760
[TBL] [Abstract][Full Text] [Related]
34. Significance of Serum Angiopoietin-2 in Patients with Hemorrhage in Adult-Onset Moyamoya Disease.
Yu J; Huang K; Pan J; Shen J; Zhan R
Biomed Res Int; 2020; 2020():8209313. PubMed ID: 32802878
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in hemorrhagic moyamoya disease.
Wan M; Duan L
Br J Neurosurg; 2015 Apr; 29(2):189-91. PubMed ID: 25365664
[TBL] [Abstract][Full Text] [Related]
36. Characterization of cortical microvascularization in adult moyamoya disease.
Czabanka M; Peña-Tapia P; Schubert GA; Woitzik J; Vajkoczy P; Schmiedek P
Stroke; 2008 Jun; 39(6):1703-9. PubMed ID: 18403740
[TBL] [Abstract][Full Text] [Related]
37. Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China.
Liu XJ; Zhang D; Wang S; Zhao YL; Teo M; Wang R; Cao Y; Ye X; Kang S; Zhao JZ
J Neurosurg; 2015 Feb; 122(2):392-9. PubMed ID: 25423267
[TBL] [Abstract][Full Text] [Related]
38. Data-Independent Acquisition-Based Serum Proteomic Profiling of Adult Moyamoya Disease Patients Reveals the Potential Pathogenesis of Vascular Changes.
Wang Z; Ji C; Han Q; Wang Z; Huang Y
J Mol Neurosci; 2022 Dec; 72(12):2473-2485. PubMed ID: 36520382
[TBL] [Abstract][Full Text] [Related]
39. 1H-NMR-based metabolomic analysis of cerebrospinal fluid from adult bilateral moyamoya disease: comparison with unilateral moyamoya disease and atherosclerotic stenosis.
Jeon JP; Yun T; Jin X; Cho WS; Son YJ; Bang JS; Kang HS; Oh CW; Kim JE; Park S
Medicine (Baltimore); 2015 May; 94(17):e629. PubMed ID: 25929894
[TBL] [Abstract][Full Text] [Related]
40. Chemokine Ligand 5 (CCL5) Derived from Endothelial Colony-Forming Cells (ECFCs) Mediates Recruitment of Smooth Muscle Progenitor Cells (SPCs) toward Critical Vascular Locations in Moyamoya Disease.
Phi JH; Suzuki N; Moon YJ; Park AK; Wang KC; Lee JY; Choi SA; Chong S; Shirane R; Kim SK
PLoS One; 2017; 12(1):e0169714. PubMed ID: 28072843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
